Crossmark

Mini-colons unlock tumour development outside the body

Crossref DOI link: https://doi.org/10.1038/s41576-024-00752-8

Published Online: 2024-06-05

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lorenzo-Martín, L. Francisco http://orcid.org/0000-0003-4717-9338
Lutolf, Matthias P. http://orcid.org/0000-0002-5898-305X
License Information

Text and Data Mining valid from 2024-06-05

Version of Record valid from 2024-06-05
More Information

Article History

First Online: 5 June 2024

Competing interests

: M.P.L. is shareholder in Doppl, which is commercializing patents on the scaffold-guided organoid technology used here.